SIOG 2020 Annual Meeting Online
The coronavirus pandemic had dramatically affected health care professionals and patients worldwide. This was a very unsettling time for everyone and everywhere. In light of the current circumstances and in abundance of caution, travel and attendance could not return to normal by the time of the 2020 SIOG Annual Conference.
The SIOG 2020 Annual Meeting Online ensured that the geriatric oncology community continued to connect and collaborate, in times when live attendance was not possible due this serious global health challenge. The pandemic had impacted the treatment and care of our older patients.
The programme comprised of:
- A short celebration of the 20th anniversary of SIOG;
- Presentations from the SIOG Working Group on COVID-19 including discussion of ethical issues;
- Rapid fire abstracts;
- Updates in Geriatric Oncology;
- General Assembly (SIOG members only).
Download the SIOG 2020 Annual Meeting Online Programme (pdf)
Article on Cancer.net website – SIOG 2020: New Research in Caring for and Treating People With Cancer Age 60 or Older
The International Society of Geriatric Oncology (SIOG) 2020 Annual Meeting Online was held virtually on October 1. In this podcast, William Dale, MD, PhD, discusses 5 studies evaluating potentially better approaches to caring for and treating people with cancer who are 60 or older.
is the leading oncology channel committed to improving cancer communication and education with the goal of optimising patient care and outcomes. ecancer’s programmes offer the healthcare community a wealth of free resources to support continued professional development. ecancer and SIOG have delivered a series of interviews of SIOG key opinion leaders and conference speakers of the online meeting.
This service has been kindly supported by unrestricted grants from Janssen Oncology.
Geriatric Syndromes and Treatment Toxicities in Older Patients with Malignant Gliomas
Andrea Wasilewski
Referral to Geriatricians among Uruguayan Haematologists
Gimena dos Santos
Exploring how older patients with advanced hematologic malignancies utilize their social network: A qualitative study
Grace DiGiovanni
Nutritional Risk status predicts overall survival of Elderly Mexican patients with advanced non-small-cell lung cancer (NSCLC)
Saul Campos Gomez
Extreme Hypofractionation Utilizing Stereotactic Body Radiation Therapy is Well Tolerated in Elderly Prostate Cancer Patients
Monica A Pernia
Prevalence of geriatric syndromes in community-dwelling elderly cancer survivors
Rei Ono
Feasibility and results of a pragmatic geriatric assessment (PGA) in a Brazilian Oncology unit. A plan to bypass the most common obstacles in implementing geriatric assessment to older patients with cancer
Antonio Fabiano Ferreira Filho
Qualitative study of a mobile health exercise intervention for older patients with myeloid neoplasms
Chandrika Sanapala
At Eisai, everything we do is dedicated to giving our first thought to patients and their families through our human health care (hhc) philosophy. We are the European hub of Tokyo-based Eisai Co. Ltd., forming part of a multinational team working across a global network of R&D facilities, manufacturing sites and marketing subsidiaries. Our collective passion and dedication to patient care is the driving force behind our efforts to discover and develop innovative medicines in a variety of therapeutic areas in which a high unmet medical need remains, including oncology and neurology. Our mission is clear; we strive to make a significant long-lasting contribution to society in an ethical, compliant and sustainable way by embodying our hhc philosophy in everything we do.
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen-emea.com. Follow us on www.twitter.com/janssenEMEA for our latest news.
Sanofi Genzyme, the specialty care global business unit of Sanofi, focuses on developing therapies in oncology, rare diseases, rare blood disorders, multiple sclerosis, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. In oncology, we are building on a rich legacy with a strong pipeline and a continued commitment to contribute meaningful solutions for patients with cancer. Through rigorous drug discovery and development rooted in cutting-edge science and innovative technologies, we are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Learn more at www.sanofigenzyme.com.
Recording
The recording is accessible free of charge for registered participants as communicated by email by the SIOG Head Office.
If you were not registered for the conference but would like to access the recording, please contact the SIOG Head Office at events@siog.org as the following fees apply
- 10€ for Low & Middle-Income Countries Non MDs, NAH, Trainees (Only available for: Non MDs, Nurses and Allied Health Professionals, Trainees from Low & Middle-Income Countries)
- 25€ for Non-MDs, NAH, Trainees (Available for Non MDs, Nurses and Allied Health Professionals, Trainees from High-Income Countries)
- 50€ for Standard (Available for all MDs, non NAH and non Trainees professionals)
Pre-SIOG 2020 Policy Webinar
The International Society of Geriatric Oncology (SIOG) had organised a webinar on the Impact of COVID-19 on older adults with cancer. SIOG was pleased to have the World Health Organisation fully represented. Public health leaders, speakers from Governments, Ministries of Health and Institutions joined the conversation. This webinar was held on September 30, 2020 at 2:00-3:00pm CET.
The COVID-19 pandemic poses a barrier to equal and evidence-based management of cancer in older adults. Age and cancer diagnosis are significant predictors of adverse outcomes of the COVID-19 infection. The International Society of Geriatric Oncology (SIOG) formed a panel of experts to develop consensus recommendations on the implications of the pandemic on several aspects of cancer care in this age group. The webinar aimed to elucidate the challenges of managing cancer in older individuals during the COVID-19 pandemic and outline relevant policies to address this challenge.
